(Reuters) – Catalent Inc said on Monday it will manufacture active ingredient for AstraZeneca Plc and the University of Oxford’s COVID-19 vaccine candidate.
It will be made at Catalent’s commercial gene therapy manufacturing facility located in Harmans, Maryland, the company said.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur)
